Arkolith/Insider Trading/ARTV/Form 4

Horan Christopher

Chief Tech Operations OfficerArtiva Biotherapeutics, Inc. (ARTV) · full profile →Form 4 · filed Dec 12, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 12, 2025Grant(A)107K—$0185K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 12, 2025Disposed to issuer(D)78K——0
Dec 12, 2025Disposed to issuer(D)9K——0
Dec 12, 2025Disposed to issuer(D)21K——0

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-317982) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML